Tag: companies

OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules

TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- Matador Technologies Inc. (“Matador” or the “Company”) (TSXV: MATA, OTCQB: MATAF, FSE: IU3), the Bitcoin Ecosystem Company, announces that it has entered into a media agreement with Flex Ecosystem Holding Ltd. d.b.a DroomDroom ("DroomDroom") dated effective June 11, 2025 (the "Media Agreement"), to provide investor relations services to the Company. DroomDroom will assist the Company in increasing investor interest and strengthening its strategic positioning in the digital asset space through curated media content and distribution.

Dublin, June 20, 2025 (GLOBE NEWSWIRE) -- The "Cancer Monoclonal Antibody Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets.com's offering.

This report contains a comprehensive listing of 632 cancer monoclonal antibody deals announced since 2016 including financial terms where available, as well as links to online deal records of actual cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Fully revised and updated, the report provides details of cancer monoclonal antibody deals from 2016 to 2025. Cancer Monoclonal Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer monoclonal antibody deals entered into by the world's leading biopharma companies.

The report provides a detailed understanding and analysis of how and why companies enter cancer monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D and commercialization of outcomes. The report includes collaboration, development, research, and licensing deals.

The initial chapters of this report provide an orientation of cancer monoclonal antibody dealmaking. It starts with an introduction to the report, followed by an overview of the trends in cancer monoclonal antibody dealmaking since 2016. The chapters progress by covering the leading deals by headline value, listing the top 25 most active companies in this domain, and reviewing detailed and comprehensive accounts of deals signed and announced since January 2016, categorized by technology type in focus.

The report also includes numerous tables and figures that illustrate the trends and activities in cancer monoclonal antibody deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z, deal type, and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Cancer Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

Driven by rising drug complexities and demand for generics, companies leverage CMOs/CDMOs for cost-effective, compliant production. The Asia-Pacific region leads with significant outsourcing and investment, while emerging trends in bioconjugation and CRO-CDMO models showcase dynamic market shifts. Access actionable insights, market trends, and competitive analyses to capitalize on growth opportunities.

The hair botox market sees opportunities in rising consumer demand for natural, safe hair treatments and at-home solutions. The shift toward chemical-free options addresses safety concerns linked to traditional methods. Companies focus on R&D for innovative products offering immediate benefits, boosting growth.